Business
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
– Updated presentation on Cogent’s potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin toxicity associated with multi-RAS inhibitors – Updated presentation on Cogent’s brain penetrant ErbB2 inhibitor, CGT4255, with evidence of synergistic activity in combination with HER2 ADCs for resistant patients WALTHAM, Mass. and BOULDER, Colo., April 17, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company foc
About this update from Cogent Biosciences, Inc.
[{"type":"image","alt":"Cogent Biosciences, Inc.","displaySize":"","headline":null,"caption":"Cogent Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":125,"url":"https://media.zenfs.com/en/globenewswire.com/8335c95b9c1a950d92b59f2ace91c141"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C3g_c01A5xhx1astIu6oTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NQ--/https://media.zenfs.com/en/globenewswire.com/8335c95b9c1a950d92b59f2ace91c141","width":300,"height":125}},"lazy":false},{"type":"text","content":"– Updated presentation on Cogent’s potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin toxicity associated with multi-RAS inhibitors","length":193,"tagName":"p"},{"type":"text","content":"– Updated presentation on Cogent’s brain penetrant ErbB2 inhibitor, CGT4255, with evidence of synergistic activity in combination with HER2 ADCs for resistant patients","length":167,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass. and BOULDER, Colo., April 17, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that preclinical data from the Company’s KRAS and ErbB2 pipeline programs will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place in April 17-22 in San Diego, CA.","length":467,"tagName":"p"},{"type":"text","content":"“As we prepare for the potential launch of bezuclastinib later this year, we are excited to share updates from two of our pipeline programs this weekend at the 2026 annual AACR meeting,” said Andrew Robbins, Cogent’s President and Chief Executive Officer. “First, we are presenting data on CGT1263, our novel pan-KRAS(ON) inhibitor, which shows best-in-class cellular potency along with evidence that its kinase selectivity advantage over multi-RAS inhibitors could drive clinical differentiation with regards to skin toxicity, a current liability of advanced clinical programs. Separately, we provide an update on CGT4255, our novel, selective ErbB2 inhibitor that was specifically designed for its best-in-class CNS penetrant properties to address a significant unmet need for HER2+ patients with brain metastases. This presentation also inc...